TY - JOUR
T1 - Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab
AU - Bersanelli, M.
AU - Gnetti, L.
AU - Azzoni, C.
AU - Bottarelli, L.
AU - Sverzellati, N.
AU - Campanini, N.
AU - Varotti, E.
AU - Corrado, Michele
AU - Parziale, R.
AU - Rapacchi, E.
AU - Caruso, G.
AU - Leonardi, F.
AU - Silini, E. M.
AU - Buti, S.
PY - 2018
Y1 - 2018
N2 - Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.
AB - Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.
KW - FHIT
KW - loss of heterozygosity
KW - renal cell carcinoma
KW - FHIT
KW - loss of heterozygosity
KW - renal cell carcinoma
UR - https://publicatt.unicatt.it/handle/10807/172128
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85050124731&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050124731&origin=inward
U2 - 10.2217/imt-2017-0160
DO - 10.2217/imt-2017-0160
M3 - Article
SN - 1750-743X
VL - 10
SP - 743
EP - 752
JO - Immunotherapy
JF - Immunotherapy
IS - 9
ER -
